(MedPage Today) — For children born with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), an investigational gene therapy showed sustained clinical efficacy and safety at a median follow-up of 7.5 years.
Among…
Source link : https://www.medpagetoday.com/pediatrics/generalpediatrics/118013
Author :
Publish date : 2025-10-17 21:42:00
Copyright for syndicated content belongs to the linked Source.
